Skip to main content
. 2021 Jan 25;7:23. doi: 10.1038/s41420-020-00383-y

Fig. 4. Effect of Cas9 mediated-MALAT1 knockdown on BT-549 colony-forming and paclitaxel/ Doxorubicin sensitivity.

Fig. 4

a Expression of the indicated MALAT1 transcripts in 1157 single cells derived from the extinction (KTN126, KTN129, and KTN206) and 592 single cells derived from the persistence (KTN102, KTN132, and KTN615) TNBC patients. Data are presented as a scatter plot with p values indicated on each plot (two-tailed t-test). b Strategy to knockdown MALAT1 promoter using dual guide RNA and Cas9 protein. c Successful deletion of the MALAT1 promoter using CRISPR/Cas9 in MDA-MB-231 and BT-549 TNBC model. QRT-PCR for MALAT1 expression in BT-549 wt and MALAT1-KO cell models. Data are presented as mean ± SD, n = 3. **p < 0.005, ***p < 0.0005. d Sanger sequencing confirming intended homozygous deletion of MALAT1 promoter in MDA-MB-231 cells. e Clonogenic assay for BT-549 and BT-549-MALAT1-KO in the presence of different concentration of Paclitaxel or Doxorubicin. f Quantification of CFU data from (e). Data are presented as mean ± SD, n = 4. ***p < 0.0005.